Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products and corn seeds in India, Germany, Bangladesh, and internationally. It provides medicines primarily in the therapeutic areas of cardiology, gynecology, diabetes, oncology, and ophthalmology; and computed tomography, X-Ray, and magnetic resonance imaging devices. In addition, the company offers consumer health products that are used as a daily health solution to treat minor illnesses, as well as sells and distributes hybrid seeds, such as corn and paddy. Further, it provides digital farming products comprising FarmRise and other digital applications, such as drones for spray services, etc., as well as provides various technologies, such as remote sensing, IoT sensors, GPS, artificial intelligence, and data analytics to monitor and manage crop growth, soil quality, weather patterns, and other factors. The company also exports its products. Bayer CropScience Limited was founded in 1863 and is based in Thane, India.
Revenue projections:
Revenue projections for BAYERCROP BAYERCROP is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.
Financial Ratios:
currentRatio
0.00000
forwardPE
26.22595
debtToEquity
3.68700
earningsGrowth
0.09600
revenueGrowth
0.17400
grossMargins
0.37460
operatingMargins
0.16776
trailingEps
131.80000
forwardEps
0.00000
Bayer CropScience Limited's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
Price projections:
Price projections for BAYERCROP Price projections for BAYERCROP have steadily increased, reflecting growing optimism about the company's future. This trend suggests that analysts believe BAYERCROP is well-positioned for continued success.
Recommendation changes over time:
Recommendations trend for BAYERCROP
BAYERCROP has recently received a buy bias from analysts, indicating that the stock is being perceived as a favorable investment. This positive sentiment could encourage investors to see BAYERCROP as a wise place to allocate their funds, potentially leading to increased interest in the company's stock.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
An in-depth look at the UK’s Q2 2025 GDP release by ONS,...
By clicking "Accept", you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our tailored marketing efforts.